The Role of 68GA-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy
Urology Journal,
Vol. 18 No. 01 (2021),
17 March 2021
,
Page 58-65
https://doi.org/10.22037/uj.v18i01.6165
Abstract
Purpose: To determine whether a 68Ga-PSMA PET/CT scan evaluation before radical prostatectomy (RP) is an
effective imaging modality for clinical local and lymph node (LN) staging compared with the pathological results.
Materials and Methods: We performed a preoperative 68Ga-PSMA PET/CT scan in 51 patients with prostate
cancer (PCa), who were scheduled for an RP operation between January 2014 and June 2016 in our clinic. The
correlation between the RP pathology and the results of the 68Ga-PSMA PET/CT scan was investigated.
Results: When the 68Ga-PSMA PET/CT scan results were evaluated according to the risk groups, intraprostatic
activity was found in 5 of 12 patients (41.7%) in the low-risk group, 15 of 19 patients in the intermediate risk group (78.9%), and 90% patients in the high-risk group. The 68Ga-PSMA PET/CT scan sensitivity, specificity, positive and negative predictive values and accuracy were calculated as 58.2%, 75.3%, 84.4%, 44%, and 63%, respectively for intraprostatic tumor localization; 68.4%, 75%, 61.9%, 80%, and %72.6%, respectively for extracapsular extension; 63.6%, 92.3%, 70%, 90%, and 86%, respectively for seminal vesicle involvement; 50%, 100%, 100%, 88%, and 89.3%, respectively for LN metastasis.
Conclusion: The 68Ga-PSMA PET/CT scan accurately demonstrates intraprostatic tumor localization in high-risk
group and presence of seminal vesicle involvement, which can help to accurately detect the target lesion before
prostate biopsy. In addition, with its high sensitivity and specificity values, 68Ga-PSMA PET/CT is a valuable imaging method for the assessment of LN metastasis in intermediate- and high-risk groups and also provides accurate nodal staging before RP.
- Lymph node dissection
- PET
- Prostate cancer
- Prostate-specific membrane antigen
- TNM staging
How to Cite
References
Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008;63:387-95.
Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res 1998;58:3009–14.
Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999;62:1322–8.
Schülke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A 2003;28;100:12590-5.
Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637–40.
Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen(PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009;15:167–72.
Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Wangler C, Mier W, et al. (68)Ga-complex lipophilicity and the targeting property of a urea based PSMA inhibitor for PET imaging. Bioconjug Chem 2012;23:688–97.
Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629–34.
Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009;69:6932–40.
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68) Ga-labelled PSMA ligand and (18)F-cholinebased PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41:11-20.
Bailey J, Piert M. Performance of (68)Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence. Curr Urol Rep 2017;9;18:84
Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, et al and The ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol 2011;24:6-15.
Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528–39.
*. Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, et al. 68Ga-PSMA-HBED-CC PET/CT detects location and extent of primary prostate cancer. J Nucl Med 2016;57:1720-1725.
*. Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ, Schrader AJ, et al. Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate Cancer. J Nucl Med 2016;57:563-7.
**. Dekalo S, Kuten J, Mabjeesh NJ, Beri A, Even-Sapir E, Yossepowitch O. 68Ga-PSMA PET/CT: Does it predict adverse pathology findings at radical prostatectomy? Urol Oncol 2019:37:574.e19-24.
Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, et al. EAU guidelines on prostate cancer. European Association of Urology. https://uroweb.org/guideline/prostate-cancer/ Edn. presented at the EAU Annual Congress Barcelona 2019. EAU Guidelines Office, Arnhem, The Netherlands. ISBN 978-94-92671-04-2.
Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008;63:387-95.
*. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al Diagnostic efficacy of 68Gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high-risk prostate cancer. J. Urol 2016;195:1436–1443.
**. van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, et al. Prospective Evaluation of 68Gallium-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Prostate Cancer. BJU Int 2016;119:209-215
Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, et al. Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. Int J Urol 2012;19:645-51.
- Abstract Viewed: 86 times
- 6165/pdf Downloaded: 51 times